The Inactivated Vaccines Market was valued at US$ 40.6 billion in 2023 and is projected to grow at a CAGR of 5.7% from 2024 ...

Among older adults in Spain, hospitalization rates from respiratory syncytial virus (RSV) infection increases progressively ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

Life science companies developing bird flu vaccines are gaining attention as the avian influenza subtype H5N1 becomes an ...

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Amongst the APEC countries and regions in the survey, hospitalisation costs per older adult in Singapore amounted to SGD ...

GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults: London, UK Saturday, March 8, 2025, 14:00 Hrs [IST] GSK plc will share its ...

MANILA, Philippines — Respiratory Syncytial Virus (RSV) is a common, contagious virus affecting the lungs and breathing ...

Moderna, Inc. ( NASDAQ: MRNA) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET All right, well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.

GSK's vaccine against respiratory syncytial virus (RSV) is one of the top prospects in its pipeline, but also one with considerable competition, so needs strong data to support the programme.